Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.53 |
| ▸ | BACE1 | P56817 | 6/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.52 |
| ▸ | ACE | P12821 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | CASP9 | P55211 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24739787 | 1.00 | CASP1 (0.53) | CASP1BACE1BACE2ACENPY1R | |
| SCHEMBL29611329 | 0.96 | CASP1 (0.55) | CASP1BACE1BACE2ACENPY1R | |
| SCHEMBL9341200 | 0.94 | BACE1 (0.52) | CASP1BACE1BACE2NPY1RNPY2R | |
| SCHEMBL9341178 | 0.94 | BACE1 (0.52) | CASP1BACE1BACE2NPY1RNPY2R | |
| SCHEMBL29612183 | 0.92 | BACE1 (0.57) | CASP1BACE1BACE2OPRD1IL23R | |
| SCHEMBL29611561 | 0.91 | BACE1 (0.58) | CASP1BACE1BACE2ACEOPRD1 | |
| SCHEMBL29611639 | 0.91 | OPRD1 (0.57) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL9341191 | 0.90 | NPY1R (0.51) | CASP1BACE1BACE2NPY1RNPY2R | |
| SCHEMBL30641532 | 0.90 | NPY1R (0.54) | BACE1BACE2NPY1RNPY2RNPY4R | |
| SCHEMBL29363254 | 0.90 | NPY1R (0.54) | BACE1BACE2NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4316460-B1 | COSMETIC COMPOSITIONS COMPRISING A SYNERGIC MIX OF ACTIVE INGREDIENTS HAVING ANTIAGING ACTIVITY | UNIFARCO S P A (IT) | 2025-09-03 | — | — | EP | claimed |
| EP-4316460-A1 | COSMETIC COMPOSITIONS COMPRISING A SYNERGIC MIX OF ACTIVE INGREDIENTS HAVING ANTIAGING ACTIVITY | Unifarco S.p.A. (IT) | 2024-02-07 | — | — | EP | claimed |
| US-12428385-B2 | Composition of a lipophilic agent for solution phase synthesis of biomolecules | Brotide Core, LLC (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4316460-B1 | COSMETIC COMPOSITIONS COMPRISING A SYNERGIC MIX OF ACTIVE INGREDIENTS HAVING ANTIAGING ACTIVITY | UNIFARCO S P A (IT) | 2025-09-03 | — | — | EP | disclosed |
| EP-4316460-A1 | COSMETIC COMPOSITIONS COMPRISING A SYNERGIC MIX OF ACTIVE INGREDIENTS HAVING ANTIAGING ACTIVITY | Unifarco S.p.A. (IT) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023244274-A2 | COMPOSITION OF A LIPOPHILIC AGENT FOR SOLUTION PHASE SYNTHESIS OF BIOMOLECULES | LI YONGFU (US) | 2023-12-21 | — | — | WO | disclosed |
| CN-116602902-B | Anti-aging composition and application thereof | 维怡美生物科技(广州)有限公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230373936-A1 | COMPOSITION OF A LIPOPHILIC AGENT FOR SOLUTION PHASE SYNTHESIS OF BIOMOLECULES | Biotide Core, LLC (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116602902-A | Anti-aging composition and application thereof | 维怡美生物科技(广州)有限公司 | 2023-08-18 | — | — | CN | disclosed |
| US-20220323534-A1 | USE OF A COMPOSITION CONTAINING AN EXTRACT OF TULIPA GESNERIANA | FRANCE COSMEPHYL-LAB (FR) | 2022-10-13 | — | — | US | disclosed |
| EP-4025179-A1 | USE OF A COMPOSITION CONTAINING AN EXTRACT OF TULIPA GESNERIANA | France Cosmephyl-Lab (FR) | 2022-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428385-B2 | Composition of a lipophilic agent for solution phase synthesis of biomolecules | LIPC, LIPA, LIPE | CASP1 3051/4885BACE1 770/4885BACE2 1322/4885 |
| US-20220323534-A1 | USE OF A COMPOSITION CONTAINING AN EXTRACT OF TULIPA GESNERIANA | GLA, NACA, GRN | CASP1 3005/4885BACE1 1844/4885BACE2 1635/4885 |
| US-20230373936-A1 | COMPOSITION OF A LIPOPHILIC AGENT FOR SOLUTION PHASE SYNTHESIS OF BIOMOLECULES | LIPC, LIPA, LIPE | CASP1 3051/4885BACE1 770/4885BACE2 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.